{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:43Z","timestamp":1792783003040,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Specialized Construction Project","award":["HBCHBBC-A01"],"award-info":[{"award-number":["HBCHBBC-A01"]}]},{"name":"Talent Project of Hubei Cancer Hospital","award":["2025HBCHQHRC018"],"award-info":[{"award-number":["2025HBCHQHRC018"]}],"id":[{"id":"https:\/\/ror.org\/05p38yh32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Talent Project of Hubei Cancer Hospital","award":["2025HBCHHHRC005"],"award-info":[{"award-number":["2025HBCHHHRC005"]}],"id":[{"id":"https:\/\/ror.org\/05p38yh32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Talent Project of Hubei Cancer Hospital","award":["2025HBCHLHRC002"],"award-info":[{"award-number":["2025HBCHLHRC002"]}],"id":[{"id":"https:\/\/ror.org\/05p38yh32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wu Jieping Fund Project","award":["320.6750.2024-21-5 and 320.6750.2025-21-13"],"award-info":[{"award-number":["320.6750.2024-21-5 and 320.6750.2025-21-13"]}]},{"name":"Hubei Province Medical Youth Talent Program"},{"name":"Chutian Talent Project","award":["CTYC002"],"award-info":[{"award-number":["CTYC002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04863-9","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:27:59Z","timestamp":1769232479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Recent advances in bispecific antibody-drug conjugates for breast cancer therapy"],"prefix":"10.1007","volume":"96","author":[{"given":"Xuan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"4","key":"4863_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, Mutebi M, Garvey G, Soerjomataram I, Fidler-Benaoudia MM (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31(4):1154\u20131162. https:\/\/doi.org\/10.1038\/s41591-025-03502-3","journal-title":"Nat Med"},{"issue":"1","key":"4863_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. Ca 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"Ca"},{"key":"4863_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, Huang L, Liu C-C, Shao Z-M, Yu K-D (2025) Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther 10:49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4","journal-title":"Signal Transduct Target Ther"},{"key":"4863_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101288","volume":"83","author":"G-Y Wu","year":"2025","unstructured":"Wu G-Y, Xiao M-Z, Hao W-C, Yang Z-S, Liu X-R, Xu D-S, Peng Z-X, Zhang L-Y (2025) Drug resistance in breast cancer: mechanisms and strategies for management. Drug Resist Updat 83:101288. https:\/\/doi.org\/10.1016\/j.drup.2025.101288","journal-title":"Drug Resist Updat"},{"issue":"1","key":"4863_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, Hou P, Cui Q, Xu Z, Wang W, Yu Z, Zhao L, He M, Wang Y, Fu C, Wei M, Yu L (2025) Antibody-Drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18(1):51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4863_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody\u2013drug conjugates come of age in oncology. Nat Rev Drug Discov 22(8):641\u2013661. https:\/\/doi.org\/10.1038\/s41573-023-00709-2","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4863_CR7","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.Cd-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE (2024) The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 14(11):2089\u20132108. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0708","journal-title":"Cancer Discov"},{"issue":"1","key":"4863_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1208\/s12248-025-01169-9","volume":"28","author":"A Beck","year":"2025","unstructured":"Beck A, D\u2019Atri V, Verhoev O, Alez-Martin L, Letissier L, Delobel A, Fleury-Souverain S, Fran\u00e7ois Y-N, Cianf\u00e9rani S, Gahoual R, Guillarme D, Hernandez-Alba O (2025) New frontiers in ADC analysis: advances in chromatography, electrophoresis, and mass spectrometry. AAPS J 28(1):34. https:\/\/doi.org\/10.1208\/s12248-025-01169-9","journal-title":"AAPS J"},{"key":"4863_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119674","journal-title":"Int J Mol Sci"},{"key":"4863_CR10","doi-asserted-by":"publisher","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, \u015eendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S (2025) Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive metastatic breast cancer. N Engl J Med 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2508668","DOI":"10.1056\/NEJMoa2508668"},{"key":"4863_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030360","author":"H Shim","year":"2020","unstructured":"Shim H (2020) Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations. Biomolecules. https:\/\/doi.org\/10.3390\/biom10030360","journal-title":"Biomolecules"},{"issue":"9","key":"4863_CR12","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L (2016) Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 76(9):2710\u20132719. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1795","journal-title":"Cancer Res"},{"issue":"6545","key":"4863_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.abg1209","volume":"372","author":"U Brinkmann","year":"2021","unstructured":"Brinkmann U, Kontermann RE (2021) Bispecific antibodies. Science 372(6545):916\u2013917. https:\/\/doi.org\/10.1126\/science.abg1209","journal-title":"Science"},{"issue":"4","key":"4863_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 23(4):301\u2013319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6","journal-title":"Nat Rev Drug Discov"},{"issue":"5\u20136","key":"4863_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.addr.2005.12.006","volume":"58","author":"JR Birch","year":"2006","unstructured":"Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58(5\u20136):671\u2013685. https:\/\/doi.org\/10.1016\/j.addr.2005.12.006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4863_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.Ccr-14-2093","volume":"21","author":"H Uppal","year":"2015","unstructured":"Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V (2015) Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 21(1):123\u2013133. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2093","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4863_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"4863_CR18","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1021\/acs.molpharmaceut.5c00090","volume":"22","author":"J Han","year":"2025","unstructured":"Han J, Xu K, Yang L, Ding Y, Wang X, Yin D, Wang J, Zhang H, Hong Z (2025) Cleavable pegylation enhances the antitumor efficacy of small-sized antibody\u2013drug conjugates. Mol Pharm 22(6):3151\u20133163. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00090","journal-title":"Mol Pharm"},{"issue":"5","key":"4863_CR19","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/c5cs00158g","volume":"45","author":"Z Liu","year":"2016","unstructured":"Liu Z, Chen X (2016) Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev 45(5):1432\u20131456. https:\/\/doi.org\/10.1039\/c5cs00158g","journal-title":"Chem Soc Rev"},{"issue":"3","key":"4863_CR20","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402x.2017.1395127","volume":"7","author":"RM Hoffmann","year":"2018","unstructured":"Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, Tutt AN, Spicer JF, Thurston DE, Crescioli S, Karagiannis SN (2018) Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology 7(3):e1395127. https:\/\/doi.org\/10.1080\/2162402x.2017.1395127","journal-title":"Oncoimmunology"},{"issue":"11","key":"4863_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1586\/14787210.2015.1079127","volume":"13","author":"KR Chan","year":"2015","unstructured":"Chan KR, Ong EZ, Mok DZ, Ooi EE (2015) Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther 13(11):1351\u20131360. https:\/\/doi.org\/10.1586\/14787210.2015.1079127","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"19","key":"4863_CR22","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.18632\/oncotarget.8574","volume":"7","author":"J Borlak","year":"2016","unstructured":"Borlak J, L\u00e4nger F, Spanel R, Sch\u00f6ndorfer G, Dittrich C (2016) Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors. Oncotarget 7(19):28059\u201328074. https:\/\/doi.org\/10.18632\/oncotarget.8574","journal-title":"Oncotarget"},{"issue":"1","key":"4863_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","volume":"328","author":"G Hale","year":"2024","unstructured":"Hale G (2024) Living in LALA land? Forty years of attenuating Fc effector functions. Immunol Rev 328(1):422\u2013437. https:\/\/doi.org\/10.1111\/imr.13379","journal-title":"Immunol Rev"},{"issue":"2","key":"4863_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/19420862.2015.1007816","volume":"7","author":"Y Mazor","year":"2015","unstructured":"Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, Yu XQ, Dall\u2019Acqua W, Wu H, Chowdhury PS (2015) Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7(2):377\u2013389. https:\/\/doi.org\/10.1080\/19420862.2015.1007816","journal-title":"MAbs"},{"issue":"4","key":"4863_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","volume":"14","author":"SC Alley","year":"2010","unstructured":"Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529\u2013537. https:\/\/doi.org\/10.1016\/j.cbpa.2010.06.170","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"4863_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4863_CR27","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S (2021) Antibody\u2013drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B 11(12):3889\u20133907. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.042","journal-title":"Acta Pharm Sin B"},{"issue":"16","key":"4863_CR28","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48(16):4361\u20134374. https:\/\/doi.org\/10.1039\/c8cs00676h","journal-title":"Chem Soc Rev"},{"issue":"2","key":"4863_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi R, de la Torre BG, Albericio F (2022) Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics 14(2):396. https:\/\/doi.org\/10.3390\/pharmaceutics14020396","journal-title":"Pharmaceutics"},{"issue":"4","key":"4863_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/bc025536j","volume":"13","author":"GM Dubowchik","year":"2002","unstructured":"Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13(4):855\u2013869. https:\/\/doi.org\/10.1021\/bc025536j","journal-title":"Bioconjug Chem"},{"issue":"7","key":"4863_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter PD, Sievers EL (2012) The discovery and development of Brentuximab Vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7):631\u2013637. https:\/\/doi.org\/10.1038\/nbt.2289","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4863_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou H-R, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I (2002) Gemtuzumab Ozogamicin, a potent and selective anti-CD33 antibody\u2009\u2013\u2009calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13(1):47\u201358. https:\/\/doi.org\/10.1021\/bc010021y","journal-title":"Bioconjug Chem"},{"issue":"1","key":"4863_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1039\/c6sc01831a","volume":"8","author":"TH Pillow","year":"2017","unstructured":"Pillow TH, Sadowsky JD, Zhang D, Yu S-F, Del Rosario G, Xu K, He J, Bhakta S, Ohri R, Kozak KR, Ha E, Junutula JR, Flygare JA (2017) Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci 8(1):366\u2013370. https:\/\/doi.org\/10.1039\/c6sc01831a","journal-title":"Chem Sci"},{"issue":"7","key":"4863_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G (2022) Bystander effect of antibody\u2013drug conjugates: fact or fiction? Curr Oncol Rep 24(7):809\u2013817. https:\/\/doi.org\/10.1007\/s11912-022-01266-4","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"4863_CR35","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Bl\u00e4ttler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426\u20134433. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4489","journal-title":"Cancer Res"},{"key":"4863_CR36","doi-asserted-by":"publisher","first-page":"1495137","DOI":"10.3389\/fimmu.2024.1495137","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, He G, Huang J, Hu L, Ma J (2024) Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis. Front Immunol 15:1495137. https:\/\/doi.org\/10.3389\/fimmu.2024.1495137","journal-title":"Front Immunol"},{"key":"4863_CR37","doi-asserted-by":"publisher","unstructured":"Widdison WC, Chari RVJ (2012) Factors involved in the design of cytotoxic payloads for antibody\u2013drug conjugates. Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. Springer, pp 93\u2013115 https:\/\/doi.org\/10.1007\/978-1-4614-5456-4_6","DOI":"10.1007\/978-1-4614-5456-4_6"},{"issue":"5","key":"4863_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N (2017) Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov 16(5):315\u2013337. https:\/\/doi.org\/10.1038\/nrd.2016.268","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4863_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","volume":"36","author":"J Long","year":"2025","unstructured":"Long J, Shao T, Wang Y, Chen T, Chen Y, Chen Y-L, Wang Q, Yu X, Yu J, He K, Lin H-b, Diao X, Wang G, Wang C (2025) PEGylation of dipeptide linker improves therapeutic index and pharmacokinetics of antibody-drug conjugates. Bioconjug Chem 36(2):179\u2013189. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00392","journal-title":"Bioconjug Chem"},{"issue":"10","key":"4863_CR40","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y (2023) Antibody\u2013drug conjugates: recent advances in payloads. Acta Pharm Sin B 13(10):4025\u20134059. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.015","journal-title":"Acta Pharm Sin B"},{"issue":"15","key":"4863_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155510","volume":"21","author":"S Ponziani","year":"2020","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ, Ippoliti R, Giansanti F (2020) Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci 21(15):5510. https:\/\/doi.org\/10.3390\/ijms21155510","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4863_CR42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC (2019) Antibody-drug conjugate-based therapeutics: state of the science. JNCI J Natl Cancer Inst 111(6):538\u2013549","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4863_CR43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1795","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law C-L (2016) Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1795","journal-title":"Cancer Res"},{"key":"4863_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther 7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4863_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","volume":"21","author":"C Janke","year":"2020","unstructured":"Janke C, Magiera MM (2020) The tubulin code and its role in controlling microtubule properties and functions. Nat Rev Mol Cell Biol 21(6):307\u2013326. https:\/\/doi.org\/10.1038\/s41580-020-0214-3","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4863_CR46","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","volume":"11","author":"M Kalim","year":"2017","unstructured":"Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, Ding Q, Chen S, Zhan J (2017) Intracellular trafficking of new anticancer therapeutics: antibody\u2013drug conjugates. Drug Des Devel Ther 11:2265\u20132276. https:\/\/doi.org\/10.2147\/DDDT.S135571","journal-title":"Drug Des Devel Ther"},{"key":"4863_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104429","volume":"107","author":"H Saber","year":"2019","unstructured":"Saber H, Simpson N, Ricks TK, Leighton JK (2019) An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. Regul Toxicol Pharmacol 107:104429. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104429","journal-title":"Regul Toxicol Pharmacol"},{"issue":"46","key":"4863_CR48","doi-asserted-by":"publisher","first-page":"e45936","DOI":"10.1097\/MD.0000000000045936","volume":"104","author":"Y Mu","year":"2025","unstructured":"Mu Y, Li J, Fan Y, Pei X (2025) Efficacy and safety of trastuzumab deruxtecan for metastatic HER2\u2009+\u2009and HER2-low breast cancer: a systematic review and meta-analysis. Medicine 104(46):e45936. https:\/\/doi.org\/10.1097\/MD.0000000000045936","journal-title":"Medicine"},{"issue":"20","key":"4863_CR49","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Research: Official J Am Association Cancer Res 10(20):7063\u20137070. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0789","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"4863_CR50","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K (2021) Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 12:3528. https:\/\/doi.org\/10.1038\/s41467-021-23793-7","journal-title":"Nat Commun"},{"issue":"3","key":"4863_CR51","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10928-021-09799-0","volume":"49","author":"C Pouzin","year":"2022","unstructured":"Pouzin C, Gibiansky L, Fagniez N, Chadjaa M, Tod M, Nguyen L (2022) Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of Tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate. J Pharmacokinet Pharmacodyn 49(3):381\u2013394. https:\/\/doi.org\/10.1007\/s10928-021-09799-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"4863_CR52","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/d1sc05243h","volume":"13","author":"N Zacharias","year":"2022","unstructured":"Zacharias N, Podust VN, Kajihara KK, Leipold D, Del Rosario G, Thayer D, Dong E, Paluch M, Fischer D, Zheng K, Lei C, He J, Ng C, Su D, Liu L, Masih S, Sawyer W, Tinianow J, Marik J, Yip V, Li G, Chuh J, Morisaki JH, Park S, Zheng B, Hernandez-Barry H, Loyet KM, Xu M, Kozak KR, Phillips GL, Shen B-Q, Wu C, Xu K, Yu S-F, Kamath A, Rowntree RK, Reilly D, Pillow T, Polson A, Schellenberger V, Hazenbos WLW, Sadowsky J (2022) A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem Sci 13(11):3147\u20133160. https:\/\/doi.org\/10.1039\/d1sc05243h","journal-title":"Chem Sci"},{"issue":"1","key":"4863_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H (2024) HER2-targeted therapies in cancer: a systematic review. Biomark Res 12(1):16. https:\/\/doi.org\/10.1186\/s40364-024-00565-1","journal-title":"Biomark Res"},{"key":"4863_CR54","doi-asserted-by":"crossref","unstructured":"Nadkarni DV (2020) Conjugations to endogenous cysteine residues. In: Tumey LN (ed) Antibody-drug conjugates: methods and protocols. Springer US, New York, NY, pp 37\u201349","DOI":"10.1007\/978-1-4939-9929-3_3"},{"key":"4863_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114269","volume":"387","author":"O Gorze\u0144","year":"2025","unstructured":"Gorze\u0144 O, \u0141\u0119cka M, \u0106wilichowska-Pu\u015blecka N, Majchrzak M, Horbach N, Wi\u015bniewski J, Jakimowicz P, Szpot P, Zawadzki M, Do\u0142\u0119ga-Kozierowski B, Kasprzak P, Turk B, Dr\u0105g M, Groborz KM, Matkowski R, Por\u0119ba M (2025) Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer. J Control Release 387:114269. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114269","journal-title":"J Control Release"},{"issue":"13Supplement","key":"4863_CR56","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1158\/1538-7445.AM2018-3914","volume":"78","author":"KJ Hamblett","year":"2018","unstructured":"Hamblett KJ, Hammond PW, Barnscher SD, Fung VK, Davies RH, Wickman GR, Hernandez A, Ding T, Galey AS, Winters GC (2018) ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers. Cancer Res 78(13Supplement):3914\u20133914","journal-title":"Cancer Res"},{"key":"4863_CR57","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, Wickman G, Abraham L, Choi K, Harbourne B, Samiotakis A, Rojas AH, Volkers G, Wong J, Atkinson CE, Baardsnes J, Worrall LJ, Browman D, Smith EE, Baichoo P, Cheng CW, Guedia J, Kang S, Mukhopadhyay A, Newhook L, Ohrn A, Raghunatha P, Zago-Schmitt M, Schrag JD, Smith J, Zwierzchowski P, Scurll JM, Fung V, Black S, Strynadka NCJ, Gold MR, Presta LG, Ng G, Dixit S (2023) An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun 14:1394. https:\/\/doi.org\/10.1038\/s41467-023-37029-3","journal-title":"Nat Commun"},{"key":"4863_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113399","volume":"218","author":"KR Francisco","year":"2021","unstructured":"Francisco KR, Varricchio C, Paniak TJ, Kozlowski MC, Brancale A, Ballatore C (2021) Structure property relationships of N-acylsulfonamides and related bioisosteres. Eur J Med Chem 218:113399. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113399","journal-title":"Eur J Med Chem"},{"issue":"11","key":"4863_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci 24(11):9674. https:\/\/doi.org\/10.3390\/ijms24119674","journal-title":"Int J Mol Sci"},{"key":"4863_CR60","doi-asserted-by":"publisher","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","volume":"33","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri K, Han H, Dotan E, Oh D-Y, Ferrario C, Tolcher A, Lee K-W, Liao C-Y, Kang Y-K, Kim YH, Hamilton E, Spira A, Patel N, Karapetis C, Rha SY, Boyken L, Woolery J, Bedard P (2022) 460MO preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol 33:S749\u2013S750. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.589","journal-title":"Ann Oncol"},{"key":"4863_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","volume":"17","author":"NK Heater","year":"2024","unstructured":"Heater NK, Warrior S, Lu J (2024) Current and future immunotherapy for breast cancer. J Hematol Oncol 17:131. https:\/\/doi.org\/10.1186\/s13045-024-01649-z","journal-title":"J Hematol Oncol"},{"issue":"22","key":"4863_CR62","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1074\/jbc.M117.818013","volume":"293","author":"V Oganesyan","year":"2018","unstructured":"Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L, Rosenthal K, Gao C, Damschroder M, Wu H, Dall\u2019Acqua W (2018) Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem 293(22):8439\u20138448. https:\/\/doi.org\/10.1074\/jbc.M117.818013","journal-title":"J Biol Chem"},{"issue":"1","key":"4863_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJM, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR (2016) A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 29(1):117\u2013129. https:\/\/doi.org\/10.1016\/j.ccell.2015.12.008","journal-title":"Cancer Cell"},{"issue":"1","key":"4863_CR64","doi-asserted-by":"publisher","first-page":"9687","DOI":"10.1038\/s41467-025-64675-6","volume":"16","author":"L Huang","year":"2025","unstructured":"Huang L, Qin G, Gong C, Sun Y, Yang H, Lv C, Liu C, Jiang L, Yuan J, Hu M, Gao X, Yang J, Li X, Si Y, Song P, Shi Y, Shi L, Yang B, Wang B (2025) Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs. Nat Commun 16(1):9687. https:\/\/doi.org\/10.1038\/s41467-025-64675-6","journal-title":"Nat Commun"},{"issue":"8","key":"4863_CR65","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","volume":"20","author":"MD Pegram","year":"2021","unstructured":"Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, Das M, Patel MR (2021) First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther 20(8):1442\u20131453. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0014","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"4863_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500132","volume":"20","author":"T Wharton","year":"2025","unstructured":"Wharton T, Spring DR (2025) Methods for the generation of single-payload antibody\u2010drug conjugates. ChemMedChem 20(10):e202500132. https:\/\/doi.org\/10.1002\/cmdc.202500132","journal-title":"ChemMedChem"},{"key":"4863_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105003","volume":"216","author":"AS Fattahi","year":"2025","unstructured":"Fattahi AS, Haghighi E (2025) Beyond monospecificity: the modular revolution of bispecific immunotherapeutics. Crit Rev Oncol Hematol 216:105003. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105003","journal-title":"Crit Rev Oncol Hematol"},{"key":"4863_CR68","doi-asserted-by":"publisher","DOI":"10.1039\/d5cb00096c","author":"Q Xue","year":"2025","unstructured":"Xue Q, Peng J, Dai W, Wu Q, Jiao J, Hu Y, Sha W, Yang Y, Yu W, Liu S, Xu T, Li JP (2025) A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy. RSC Chemical Biology. https:\/\/doi.org\/10.1039\/d5cb00096c","journal-title":"RSC Chemical Biology"},{"key":"4863_CR69","doi-asserted-by":"publisher","unstructured":"Park JJ, Gao B, Beecroft C, Wilkinson KJ, Parsonson A, Zhang K, Yan X, Wang N (2024)Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. | Journal of Clinical Oncology42 (16_suppl):3038-3038. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3038}","DOI":"10.1200\/JCO.2024.42.16_suppl.3038"},{"issue":"1","key":"4863_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh D-Y, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, Jung KH, \u0141ugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee J-Y (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42(1):47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005","journal-title":"J Clin Oncol"},{"key":"4863_CR71","doi-asserted-by":"crossref","unstructured":"Park JJ, Gao B, Beecroft C, Wilkinson KJ, Parsonson A, Zhang K, Yan X, Wang N (2024) Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2024.42.16_suppl.3038"},{"key":"4863_CR72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536699100","author":"AD Ej","year":"2003","unstructured":"Ej AD, An K, Mj BPP (2003) The tetraspanin CD63 enhances the internalization of the H,K-ATPase beta-subunit. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.2536699100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"4863_CR73","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.yexcr.2008.09.020","volume":"315","author":"MS Pols","year":"2009","unstructured":"Pols MS, Klumperman J (2009) Trafficking and function of the tetraspanin CD63. Exp Cell Res 315(9):1584\u20131592. https:\/\/doi.org\/10.1016\/j.yexcr.2008.09.020","journal-title":"Exp Cell Res"},{"issue":"15","key":"4863_CR74","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1021\/acs.jctc.4c00606","volume":"20","author":"R Calinsky","year":"2024","unstructured":"Calinsky R, Levy Y (2024) Histidine in proteins: pH-dependent interplay between \u03c0\u2013\u03c0, cation\u2013\u03c0, and CH\u2013\u03c0 interactions. J Chem Theory Comput 20(15):6930\u20136945. https:\/\/doi.org\/10.1021\/acs.jctc.4c00606","journal-title":"J Chem Theory Comput"},{"issue":"5","key":"4863_CR75","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jaci.2025.05.028","volume":"156","author":"D Brigger","year":"2025","unstructured":"Brigger D, Guntern P, Pennington LF, van Brummelen R, Jardetzky TS, Eggel A (2025) High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo. J Allergy Clin Immunol 156(5):1290\u20131302. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.028","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4863_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/antib12030055","volume":"12","author":"FD Smith","year":"2023","unstructured":"Smith FD, Pierce RH, Thisted T, van der Horst EH (2023) Conditionally active, pH-sensitive immunoregulatory antibodies targeting VISTA and CTLA-4 lead an emerging class of cancer therapeutics. Antibodies 12(3):55. https:\/\/doi.org\/10.3390\/antib12030055","journal-title":"Antibodies"},{"issue":"1","key":"4863_CR77","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF02890428","volume":"61","author":"MJ Metzelaar","year":"1992","unstructured":"Metzelaar MJ, Schuurman H-J, Heijnen HFG, Sixma JJ, Nieuwenhuis HK (1992) Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies. Virchows Arch 61(1):269\u2013277. https:\/\/doi.org\/10.1007\/BF02890428","journal-title":"Virchows Arch"},{"issue":"2","key":"4863_CR78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4161\/mabs.27705","volume":"6","author":"BE de Goeij","year":"2014","unstructured":"de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW (2014) HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. mAbs 6(2):392\u2013402. https:\/\/doi.org\/10.4161\/mabs.27705","journal-title":"mAbs"},{"issue":"11","key":"4863_CR79","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","volume":"15","author":"BECG de Goeij","year":"2016","unstructured":"de Goeij BECG, Vink T, ten Napel H, Breij ECW, Satijn D, Wubbolts R, Miao D, Parren PWHI (2016) Efficient payload delivery by a bispecific antibody\u2013drug conjugate targeting HER2 and CD63. Mol Cancer Ther 15(11):2688\u20132697. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0364","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4863_CR80","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/1535-7163.MCT-16-0839","volume":"16","author":"MP Kelly","year":"2017","unstructured":"Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D\u2019Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR (2017) Preclinical activity of the novel anti-prolactin receptor (PRLR) antibody\u2013drug conjugate REGN2878-DM1 in PRLR-positive breast cancers. Mol Cancer Ther 16(7):1299\u20131311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0839","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"4863_CR81","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","volume":"16","author":"J Andreev","year":"2017","unstructured":"Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D, Daly C, Olson W, Thurston G (2017) Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther 16(4):681\u2013693. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0658","journal-title":"Mol Cancer Ther"},{"issue":"49","key":"4863_CR82","doi-asserted-by":"publisher","first-page":"34296","DOI":"10.1074\/jbc.M109.039727","volume":"284","author":"A Tuli","year":"2009","unstructured":"Tuli A, Sharma M, Capek HL, Naslavsky N, Caplan S, Solheim JC (2009) Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation. J Biol Chem 284(49):34296\u201334307. https:\/\/doi.org\/10.1074\/jbc.M109.039727","journal-title":"J Biol Chem"},{"issue":"4","key":"4863_CR83","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","volume":"28","author":"RM DeVay","year":"2017","unstructured":"DeVay RM, Delaria K, Zhu G, Holz C, Foletti D, Sutton J, Bolton G, Dushin R, Bee C, Pons J, Rajpal A, Liang H, Shelton D, Liu S-H, Strop P (2017) Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug Chem 28(4):1102\u20131114. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00013","journal-title":"Bioconjug Chem"},{"issue":"1","key":"4863_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","volume":"371","author":"RA Mitchell","year":"2018","unstructured":"Mitchell RA, Luwor RB, Burgess AW (2018) Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics. Exp Cell Res 371(1):1\u201319. https:\/\/doi.org\/10.1016\/j.yexcr.2018.08.009","journal-title":"Exp Cell Res"},{"issue":"7","key":"4863_CR85","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463\u2013475. https:\/\/doi.org\/10.1038\/nrc2656","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4863_CR86","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.breast.2014.06.011","volume":"23","author":"AS Berghoff","year":"2014","unstructured":"Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P (2014) Co-overexpression of HER2\/HER3 is a predictor of impaired survival in breast cancer patients. Breast (Edinburgh Scotland) 23(5):637\u2013643. https:\/\/doi.org\/10.1016\/j.breast.2014.06.011","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"11","key":"4863_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx065","volume":"109","author":"LJ Schwarz","year":"2017","unstructured":"Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL (2017) An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2\u2009+\u2009breast cancers with ERBB ligand overexpression. J Natl Cancer Inst 109(11):djx065. https:\/\/doi.org\/10.1093\/jnci\/djx065","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"4863_CR88","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","volume":"45","author":"H-F Zong","year":"2024","unstructured":"Zong H-F, Li X, Han L, Wang L, Liu J-J, Yue Y-L, Chen J, Ke Y, Jiang H, Xie Y-Q, Zhang B-H, Zhu J-W (2024) A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol Sin 45(8):1727\u20131739. https:\/\/doi.org\/10.1038\/s41401-024-01279-8","journal-title":"Acta Pharmacol Sin"},{"issue":"11","key":"4863_CR89","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, J\u00e4nne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389\u20131400. https:\/\/doi.org\/10.1038\/nm.3388","journal-title":"Nat Med"},{"key":"4863_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102436","volume":"109","author":"JZ Drago","year":"2022","unstructured":"Drago JZ, Ferraro E, Abuhadra N, Modi S (2022) Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev 109:102436. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102436","journal-title":"Cancer Treat Rev"},{"key":"4863_CR91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.critrevonc.2016.03.009","volume":"101","author":"S Temraz","year":"2016","unstructured":"Temraz S, Mukherji D, Shamseddine A (2016) Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Crit Rev Oncol Hematol 101:151\u2013157. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.03.009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"318","key":"4863_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005125","volume":"7","author":"JJ Tao","year":"2014","unstructured":"Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M (2014) Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 7(318):ra29. https:\/\/doi.org\/10.1126\/scisignal.2005125","journal-title":"Sci Signal"},{"issue":"7Supplement","key":"4863_CR93","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","volume":"83","author":"W Wan","year":"2023","unstructured":"Wan W, Zhao S, Zhuo S, Zhang Y, Chen L, Li G, Renshaw B, Khalili JS, Xiao S, Zhu Y (2023) Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res 83(7Supplement):2642\u20132642. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2642","journal-title":"Cancer Res"},{"key":"4863_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104874","author":"J Zhang","year":"2025","unstructured":"Zhang J, Wu J, Du Y, Meng Y, Xiao S, Zhu H, Zhu Y (2025) 302MO phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic breast cancer (BC). ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104874","journal-title":"ESMO Open"},{"issue":"6","key":"4863_CR95","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/cbin.11340","volume":"44","author":"M London","year":"2020","unstructured":"London M, Gallo E (2020) Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int 44(6):1267\u20131282. https:\/\/doi.org\/10.1002\/cbin.11340","journal-title":"Cell Biol Int"},{"issue":"3","key":"4863_CR96","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.gpb.2016.02.004","volume":"14","author":"M Li","year":"2016","unstructured":"Li M, Liu Y (2016) Topoisomerase I in human disease pathogenesis and treatments. Genomics Proteomics Bioinformatics 14(3):166\u2013171. https:\/\/doi.org\/10.1016\/j.gpb.2016.02.004","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"7","key":"4863_CR97","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","volume":"34","author":"D Kweekel","year":"2008","unstructured":"Kweekel D, Guchelaar H-J, Gelderblom H (2008) Clinical and pharmacogenetic factors associated with Irinotecan toxicity. Cancer Treat Rev 34(7):656\u2013669. https:\/\/doi.org\/10.1016\/j.ctrv.2008.05.002","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4863_CR98","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL (2011) Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochemistry: Official J Histochem Soc 59(7):701\u2013710. https:\/\/doi.org\/10.1369\/0022155411410430","journal-title":"J Histochem Cytochemistry: Official J Histochem Soc"},{"issue":"5","key":"4863_CR99","doi-asserted-by":"publisher","first-page":"e96993","DOI":"10.1371\/journal.pone.0096993","volume":"9","author":"F Ambrogi","year":"2014","unstructured":"Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E, Alberti S (2014) Trop-2 is a determinant of breast cancer survival. PLoS One 9(5):e96993. https:\/\/doi.org\/10.1371\/journal.pone.0096993","journal-title":"PLoS One"},{"issue":"9","key":"4863_CR100","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, Xing D, Yan S, Zhang M (2024) Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics 14(9):3674\u20133692. https:\/\/doi.org\/10.7150\/thno.98178","journal-title":"Theranostics"},{"issue":"16_suppl","key":"4863_CR101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e13138","volume":"43","author":"H Yao","year":"2025","unstructured":"Yao H, Liu J, Zeng Y, Huang Z, Wang J, Cao Y, Wang Y, Wu W, Yang Y-P, Yu F, Lai X, Zong H, Lv D, Wu J, Ye S, Xu T, Wang Z, Tang X, Xu R, Song E (2025) First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results. J Clin Oncol 43(16_suppl):e13138\u2013e13138. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e13138","journal-title":"J Clin Oncol"},{"key":"4863_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720","volume":"125","author":"RS Heist","year":"2024","unstructured":"Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F (2024) Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 125:102720. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102720","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"4863_CR103","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cort\u00e9s J, O\u2019Shaughnessy J, Di\u00e9ras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04863-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04863-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:28:01Z","timestamp":1769232481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04863-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4863"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04863-9","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"15"}}